000			02079 a2200541 4500
005			20250515182644.0
264		0	_c20091224
008			200912s 0 0 eng d
022			_a1755-3245
024	7		_a10.1093/cvr/cvp274 _2doi
040			_aNLM _beng _cNLM
100	1		_aLacerda, Lydia
245	0	0	_aIschaemic postconditioning protects against reperfusion injury via the SAFE pathway. _h[electronic resource]
260			_bCardiovascular research _cNov 2009
300			_a201-8 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAndrostadienes _xpharmacology
650	0	4	_aAnimals
650	0	4	_aDisease Models, Animal
650	0	4	_aExtracellular Signal-Regulated MAP Kinases _xantagonists & inhibitors
650	0	4	_aFlavonoids _xpharmacology
650	0	4	_aGlycogen Synthase Kinase 3 _xmetabolism
650	0	4	_aGlycogen Synthase Kinase 3 beta
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Knockout
650	0	4	_aMyocardial Infarction _xmetabolism
650	0	4	_aMyocardial Reperfusion Injury _xmetabolism
650	0	4	_aMyocardium _xmetabolism
650	0	4	_aPhosphatidylinositol 3-Kinases _xmetabolism
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aPhosphorylation
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aReceptors, Tumor Necrosis Factor, Type I _xgenetics
650	0	4	_aReceptors, Tumor Necrosis Factor, Type II _xdeficiency
650	0	4	_aSTAT3 Transcription Factor _xantagonists & inhibitors
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aTumor Necrosis Factor-alpha _xdeficiency
650	0	4	_aTyrphostins _xpharmacology
650	0	4	_aWortmannin
700	1		_aSomers, Sarin
700	1		_aOpie, Lionel H
700	1		_aLecour, Sandrine
773	0		_tCardiovascular research _gvol. 84 _gno. 2 _gp. 201-8
856	4	0	_uhttps://doi.org/10.1093/cvr/cvp274 _zAvailable from publisher's website
999			_c19073045 _d19073045